Cybin Inc
Change company Symbol lookup
Select an option...
CLXPF Cybin Inc
HBAN Huntington Bancshares Inc
MOGO Mogo Inc
VYGR Voyager Therapeutics Inc
PDAC^ Peridot Acquisition Corp
ABB Abb Ltd
TLT iShares 20+ Year Treasury Bond ETF
TBT ProShares UltraShort 20+ Year Treasury
GLD SPDR® Gold Shares
SLV iShares Silver Trust
Go


Based in Canada
Company profile

Cybin Inc., formerly Clarmin Explorations Inc., is a Canada-based life sciences company. The Company is focused on developing psychedelic pharmaceutical and non-psychedelic nutraceutical-based products. Its subsidiaries include Natures Journey Inc. and Serenity Life Sciences Inc. Serenity Life Sciences Inc. is focused on research and development of psilocybin-based medications. Natures Journey Inc. operates the Journey brand, which specializes in developing medicinal mushroom products. It has a drug delivery platform developed to administer psychedelic therapies and bypass liver metabolism. The Company also focus is on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols.

Closing Price
$1.56
Day's Change
0.0276 (1.80%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.60
Day's Low
1.51
Volume
(Heavy Day)
Volume:
416,260

10-day average volume:
227,591
416,260

Display:

Providers:

UpdateCancel
6 providers
June 11, 2021
Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the H.C. Wainwright...(BusinessWire)

June 08, 2021
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

The illegal drugs of the 1960's are becoming highly valued drugs for various new therapeutic uses across a growing list of maladies. The door of previously prohibited drugs has been opening and it appears that there will be more treatments, more...(PR Newswire)

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it will co-sponsor a randomized, placebo-controlled trial of psychedelic-assisted...(BusinessWire)

June 02, 2021
Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the 2021 LD Micro Invitational XI. The presentation...(BusinessWire)

June 01, 2021
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine's Psychedelic Effects on Cerebral Cortex Hemodynamics

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel's feasibility study of its Kernel Flow technology to measure...(BusinessWire)

May 28, 2021
Cybin to Present at the Jefferies Virtual Healthcare Conference 2021

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Jefferies Virtual...(BusinessWire)

May 26, 2021
Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that brings the potential to obtain patent...(BusinessWire)

May 20, 2021
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new provisional patent application in support of its ongoing drug candidate...(BusinessWire)

March 26, 2021
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution

NetworkNewsAudio - Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, "Science Drives Surging Interest in Psychedelic Therapeutics." To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast (Globe Newswire)

March 25, 2021
Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges

via InvestorWire -- Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork ("IBN"), a multifaceted financial news and publishing company...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.